Literature DB >> 15109028

In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis.

Luciana S Ferreira1, Gilson A Ramaldes, Elzíria A Nunan, Lucas A M Ferreira.   

Abstract

Paromomycin (PA), a very hydrophilic antibiotic, has been tested as an alternative topical treatment against cutaneous leishmaniasis (CL). Although this treatment has shown promising results, it has not been successful in accelerating the recovery in most cases. This could be attributed to the low skin penetration of PA. Liposomal formulations usually provide sustained and enhanced drug levels in skin. The aim of this study was to prepare liposomal formulations containing PA and to investigate their potential as topical delivery systems of this antileishmanial. Large multilamellar vesicles (MLVs) were prepared by conventional solvent evaporation method. Large unilamellar vesicles (LUVs) were prepared by reverse-phase evaporation method. The lipids used were soybean phosphatidylcholine (PC) and PC:cholesterol (CH) (molar ratio 1:1). The skin permeation experiments across stripped and normal hairless mice skin were performed in modified Franz diffusion cells. The PA entrapment in LUV liposomes (20.4 +/- 2.2%) was higher than that observed for MLV liposomes (7.5 +/- 0.9%). Drug entrapment was 41.9 +/- 6.2% and 27.2 +/- 2.4% for PC and PC:CH LUV, respectively. The skin permeation was 1.55 +/- 0.31%, 1.29 +/- 0.40%, 0.20 +/- 0.08%, and 0.50 +/- 0.19% for PC LUV, PC:CH LUV, empty LUV +/- PA and aqueous solution, respectively. Controlled topical delivery, across stripped skin, was observed for PA entrapped in LUV liposomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109028     DOI: 10.1081/ddc-120030423

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  10 in total

1.  Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

Authors:  Antara Banerjee; Manjarika De; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

2.  Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Authors:  Katrien Van Bocxlaer; Eric Gaukel; Deirdre Hauser; Seong Hee Park; Sara Schock; Vanessa Yardley; Ryan Randolph; Jacob J Plattner; Tejal Merchant; Simon L Croft; Robert T Jacobs; Stephen A Wring
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 3.  Liposomal drug delivery systems for the treatment of leishmaniasis.

Authors:  Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato
Journal:  Parasitol Res       Date:  2022-09-16       Impact factor: 2.383

4.  Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis.

Authors:  Nowsheen Goonoo; Marie Andrea Laetitia Huët; Itisha Chummun; Nancy Karuri; Kingsley Badu; Fanny Gimié; Jonas Bergrath; Margit Schulze; Mareike Müller; Archana Bhaw-Luximon
Journal:  R Soc Open Sci       Date:  2022-06-15       Impact factor: 3.653

5.  Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.

Authors:  William R Ravis; Alejandro Llanos-Cuentas; Nestor Sosa; Mara Kreishman-Deitrick; Karen M Kopydlowski; Carl Nielsen; Kirsten S Smith; Philip L Smith; Janet H Ransom; Yuh-Jing Lin; Max Grogl
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

6.  Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.

Authors:  Mahmoud R Jaafari; Neda Bavarsad; Bibi Sedigheh Fazly Bazzaz; Afshin Samiei; Dina Soroush; Serajodin Ghorbani; Mohammad M Lotfi Heravi; Ali Khamesipour
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  Treatment of cutaneous lesion of 20 years' duration caused by leishmanization.

Authors:  Ali Khamesipour; Azam Abbasi; Alireza Firooz; Akram Mir Amin Mohammadi; Seyed Ebrahim Eskandari; Mahmoud R Jaafari
Journal:  Indian J Dermatol       Date:  2012-03       Impact factor: 1.494

8.  Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney.

Authors:  Heibatullah Kalantari; Ali Asghar Hemmati; Neda Bavarsad; Annahita Rezaie; Shahin Ahmadi
Journal:  Jundishapur J Nat Pharm Prod       Date:  2014-10-26

9.  Nanoemulsions with Chloroaluminium Phthalocyanine and Paromomycin for Combined Photodynamic and Antibiotic Therapy for Cutaneous Leishmaniasis.

Authors:  Sandra Milena Leal Pinto; Luis Alexandre Muehlmann; Lucía Liliana Mantilla Ojeda; Angélica María Vera Arias; Martha Viviana Roa Cordero; María de Fátima Menezes Almeida Santos; Ricardo Bentes Azevedo; Patricia Escobar Rivero
Journal:  Infect Chemother       Date:  2021-06

10.  Development of a liposome-based formulation for vitamin K1 nebulization on the skin.

Authors:  Virginia Campani; Dario Marchese; Maria Teresa Pitaro; Michele Pitaro; Paolo Grieco; Giuseppe De Rosa
Journal:  Int J Nanomedicine       Date:  2014-04-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.